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T
 
wo questions have dominated the field of human can-
cer immunology throughout its history. Do cancer-
specific antigens exist and, if so, are they recognized by the
autologous host? Until recently, attempts to provide defini-
tive answers to these questions have not been rewarded
with much success. However, as in so many other areas of
research where technical advances provide the means to
advance fields, this has also been the case in cancer immu-
nology. With regard to T cell–defined tumor antigens, the
discovery of IL-2 permitted the isolation of stable lines of
cytotoxic T cells with specificity for autologous melanoma
cells (1), and this, in turn, led to the identification of T
cell–recognized epitopes on human tumor cells (2, 3).
With regard to antibody-defined tumor antigens, hybri-
doma technology for generating mouse and human mono-
clonal antibodies and advances in cloning and biochemical
characterization of tumor antigens have given rise to an in-
creasingly detailed picture of the surface antigenic structure
of cancer cells. Nevertheless, these serological efforts did
not bring answers to the issue of tumor-specific recognition
by the humoral immune system of the tumor-bearing host.
For this purpose, a new approach introduced by Pfreund-
schuh and his colleagues Sahin and Türeci at the University
of Saarland (Homburg, Germany; references 4–6) has inau-
gurated a new phase in cancer serology, bringing with it
the prospect of providing a comprehensive view of the im-
mune recognition of human cancer. They call their ap-
proach SEREX, for serological analysis of recombinant
cDNA expression libraries of human tumors with autolo-
gous serum. In their initial application of the method, tu-
mor antigens such as MAGE and tyrosinase that had origi-
nally been defined as T cell–recognized epitopes were
detected by autologous antibody. SEREX analysis has now
identified a series of provocative cancer antigens that have
relevance to the etiology, diagnosis, and therapy of cancer.
What is so encouraging about SEREX is that it provides a
way to analyze the humoral immune response to intracellu-
lar cancer antigens, a generally impenetrable forest for can-
cer serologists in the past.
Two papers related to antigens defined by SEREX have
 
appeared in 
 
The Journal of Experimental Medicine
 
 (7, 8). As
background for these studies, this commentary is intended
to give a historical perspective to the development of
SEREX and to review the current status of SEREX analy-
sis of human cancer.
 
A Brief History of Cancer Serology.
 
The search for anti-
bodies that distinguish cancer cells from normal cells is one
of the longest uninterrupted inquiries in cancer research
(9). The history of this pursuit can be divided into four
phases. The first, dominated by immunologists such as
Witebsky and Hirszfeld, dealt mainly with the analysis of
heteroimmune sera obtained from rabbits and other animals
immunized with human cancer (10). The challenge, gener-
ally unmet, was to remove antibodies reactive with normal
tissue antigens, and a variety of absorption techniques were
devised to accomplish this. Complement fixation and later
agar gel immunoprecipitation provided the primary assay sys-
tems to analyze the heteroimmune sera. Although little of
enduring value came from this vast effort, two useful anti-
gens were identified: alpha fetoprotein, a serum marker for
hepatoma and germ cell tumors (11), and carcinoembry-
onic antigen (CEA), a serum marker for colon and other
epithelial cancers (12). The second phase in this odyssey
was initiated by the work of Gorer, a scientist best known
for his discovery of the mouse major histocompatibility locus.
Gorer also had an intense interest in tumor antigens and he
introduced the approaches and test systems involving cyto-
toxic alloantibodies prepared in inbred mice that led to the
serological dissection of normal and malignant lymphoid
cells and the discovery of cell surface “differentiation anti-
gens” such as thymus leukemia (TL), Ly1, Lyt2 (CD8),
Thy-1, and PCA (13), and endogenous retroviral-coded
 
antigens such as GCSA, G
 
IX
 
, and ML (14). The emergence
of hybridoma technology transformed the field of serology
and opened the floodgates for identifying new cell surface
antigens in mice and humans and for analyzing the anti-
genic phenotype of human cancer. Although there was
great hope that monoclonal antibodies would uncover tu-
mor-specific antigens in humans, this has not proven to be
the case. Rather, experience has shown that even the most
restricted tumor antigen generally turns out to be a re-
stricted normal differentiation antigen (15). In addition to
the use of polyclonal and monoclonal antibodies of heter-
ologous and allogeneic origin in the search for tumor-spe-
cific antigens, there has been a sustained effort to determine
whether the autologous host recognizes cancer cells. To es-
tablish as rigorous and unambiguous a serological test sys-
tem as possible for this purpose, an approach called autolo-
gous typing was developed (16), initiating what can now
be seen as the third phase in human cancer serology. The
intention of autologous typing was to restrict the analysis to
autologous reagents (tumor cells, serum, normal cells such
as fibroblasts, and lymphocytes from the same patient) to
eliminate the contribution of alloantigens in the reactions
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observed and to establish tumor specificity by absorption
with autologous normal cells. With the exception of leuke-
mia and lymphoma cells, cultured tumor cell lines were re-
quired for autologous typing, and this limited analysis to
tumor types that could be adapted to growth in vitro with
some regularity, i.e., melanoma (17, 18), renal cancer (19),
and brain cancer (20). The conclusion coming from the au-
tologous typing of a large series of patients is that a small
fraction of patients develop demonstrable autologous anti-
body with specificity for cell surface antigens of the tumor.
However, with few exceptions (21, 22), molecular charac-
terization of the antigen was generally beyond reach, pri-
marily because the antibodies were not of sufficient titer to
monitor biochemical purification or cloning. With the de-
velopment of SEREX, ushering in the fourth phase of can-
cer serology, autologous typing can now be carried to a
new level of specificity analysis and comprehensiveness that
could only be dreamed about in the past.
 
SEREX Methodology.
 
Although the concept behind
SEREX is straightforward, there were a number of techni-
cal challenges that needed to be resolved. One of the most
crucial involved eliminating antibodies in human sera that
react with bacterial or phage components. This is not a
trivial exercise and is absolutely essential because such con-
taminating antibodies completely obscure the detection of
other classes of antibodies. The presence of variable num-
bers of B cells in tumors gives rise to IgG mRNA, which is
expressed and detected in SEREX, and a strategy to elimi-
nate these clones also needed to be developed. There was
an initial suspicion that the majority of antibodies detected
in SEREX would be autoantibodies with little or no rele-
vance to cancer. Experience has shown that antibodies such
as those related to known autoimmune states have not been
overrepresented in SEREX studies to date, and this may
have to do with Pfreundschuh and his colleagues’ decision
to exclude IgM from the analysis and to focus on high ti-
tered IgG antibodies.
In their original analysis, Sahin et al. (4) established the
basic strategy for the initial study of SEREX-defined
clones: (
 
a
 
) DNA sequencing to establish identity, similarity,
or uniqueness with regard to genes in the existing data
banks and the search for possible structural (e.g., muta-
tional) abnormalities, (
 
b
 
) analysis of the mRNA expression
pattern in normal tissues and in tumors, and (
 
c
 
) immunoge-
nicity as measured by the frequency of antibodies in a lim-
ited panel of sera from normal individuals and patients with
the same tumor type. Subsequent analysis of interesting
clones showing cancer relatedness in terms of sequence ab-
normalities, expression patterns, or seroreactivity includes
chromosomal mapping, generating monoclonal antibodies
for biochemical and immunohistochemical studies, and se-
rological surveys of antibody reactivity in patients with var-
ious types of human cancer.
 
Categories of SEREX-defined Antigens.
 
During the past
two years, SEREX has been applied to a range of tumor
types, including melanoma, renal cancer, astrocytoma,
Hodgkin’s disease (4), esophageal cancer (23), lung cancer
 
(24, 25), colon cancer (26), gastric cancer, breast cancer,
and prostate cancer. (A SEREX collaborative group has
been established by the Ludwig Institute for Cancer Re-
search involving investigators at the University of Saarland
[Homburg, Germany]; Ludwig Institute Branches in New
York, San Diego, CA, Melbourne [Australia], and London
[UK, University College]; Aichi Cancer Center [Nagoya,
Japan]; Krankenhaus Nordwest [Frankfurt, Germany]; Mie
University School of Medicine [Mie, Japan] Moscow State
University [Moscow, Russia], and the Institute of Molecu-
lar Biology and Genetics [Kyiv, Ukraine].) This survey has
identified a large number of tumor antigens, 
 
.
 
400, only a
small fraction of which has been analyzed beyond the initial
sequencing stage. Approximately one third of the SEREX-
defined genes are novel. 
Table 1 lists the categories of tumor antigens that have
been identified to date. The prime example of a mutational
antigen is p53 isolated from a case of colon cancer, showing
the potential of SEREX to identify etiologically relevant
gene products in cancer. Three SEREX-defined antigens,
which we have called 3p antigens, are encoded for by the
p21 region on chromosome 3 (25 and Gordan, J.D., and M.J.
Scanlan, unpublished data), a region known to be a hot
spot of genetic abnormalities in many cancer types. Al-
though mutation may likely be the underlying mechanism
for the immunogenicity of these antigens, no mutations
have been detected as yet in the coding sequences of the 3p
antigens. The classic differentiation antigen tyrosinase has
been detected in SEREX, and other examples, including a
gastrointestinal tract–related differentiation antigen galec-
tin 4, have been identified (26). Several antigens coded for
by amplified or overexpressed genes have also been identi-
fied, e.g., a new isoform of carbonic anhydrase in renal
cancer (4), aldolase A (25) and eIF-4
 
g 
 
(24) in lung cancer,
and galectin 9 in Hodgkin’s disease (27), indicating that an-
tigen overexpression can lead to immunogenicity, as it does
in the case of HER2/neu (28). 
A fascinating category of tumor antigens, first discovered
in the analysis of T cell–recognized epitopes, has been re-
ferred to as cancer-testis (CT) antigens (Table 2). CT anti-
gens are expressed by a variable proportion, 
 
z
 
10–40%, of a
wide range of different human tumor types. In normal tis-
sues, expression is highly restricted, with testis being the
sole or predominant site of CT expression. The CT
 
1
 
 cell
type in the testis appears to be spermatogonia (33). Three
antigens in this category, MAGE (3), BAGE (34), and
GAGE (35), were initially identified as targets for cytotoxic
T cells. HOM-MEL-40/SSX2, NY-ESO-1, SCP1, and
CT7 were uncovered by SEREX analysis. In total, there
are now seven genes or gene families belonging to the CT
category, and four of them have been shown to be coded
for by the X chromosome (MAGE, GAGE, SSX, and NY-
ESO-1). Since no evidence has been obtained for mutation
or other gene rearrangements involving CT-coding genes
(the single exception to this is the characteristic t[X;18]
translocation of synovial sarcoma that involves SSX genes
(36), but this translocation is not found in other SSX ex- 
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pressing cancers.), the likely explanation for expression of
CT antigens in cancer cells is gene activation or derepres-
sion, and the well-known precedent for this in animal sys-
tems is the anomalous expression of TL antigens in the leu-
kemias of TL
 
2
 
 mice (37). De Smet et al. (38) have
correlated MAGE expression with the state of global hy-
pomethylation generally associated with cancer and sper-
matogenesis. However, this cannot be the whole explana-
tion because CT antigens are not coordinately expressed,
and certain tumor types, such as colon cancer, rarely ex-
press known CT antigens. SCP1, the only CT antigen with
a known function, is a synaptonemal complex protein in-
volved in chromosome reduction during meiosis, and it is
intriguing to speculate what role aberrant expression of a
meiotic protein in a somatic cell plays in the origins and
progression of cancer. CT7 is the most recent CT antigen
defined by SEREX. (Because the function of only one CT
antigen is known, a standardized nomenclature for these
antigens has not been established. We have suggested that
new CT antigens be numbered in the order of their dis-
covery, e.g., CT7 for the seventh CT antigen or antigen
family to be identified. In the case of CT antigens belong-
ing to a multigene family, each member would be distin-
guished by a number following the CT designation, e.g.,
CT7.1, CT7.2, etc.) The CT7 gene encodes a protein with
 
.
 
1,000 amino acid residues, with the COOH terminus
highly homologous to the MAGE-10, and other MAGE
genes over a 
 
z
 
200 amino acid stretch. Sequences N-termi-
nal to this segment, however, show no homology to the
MAGE family. To find new members of the CT family,
SEREX analysis is being extended to screening expression
libraries derived from normal testis (30, 32) and tumor cell
lines expressing one or more of the known CT antigens.
 
Future Directions.
 
The rise in interest in T cell, particu-
larly CTL, recognition of cancer over the past two decades
has been associated with a corresponding diminution in at-
tention paid to the humoral immune response to cancer. As
the cellular and humoral immune systems work in concert,
it would be surprising if cancer antigens induced only a cel-
lular response and no antibodies. In fact, SEREX has
taught us that antigens, such as MAGE and NY-ESO-1,
elicit both cellular and humoral immune responses, and we
 
Table 1.
 
Categories of SEREX-identified Human Tumor Antigens
 
Antigen category Examples Tumor source References
Mutational p53 Colon cancer 26
3p NY-LU-12 Lung cancer 25
Differentiation Tyrosinase Melanoma 4
Galectin 4 Colon cancer 26
Amplified/overexpressed Carbonic anhydrase Renal cancer 4
Galectin 9 Hodgkin’s disease 27
Aldolase A Lung cancer 25
eIF-4
 
g
 
Lung cancer 24
Retroviral HERV-K10 Renal cancer 5
Splice variant Restin Hodgkin’s disease 4
NY-CO-38 Colon cancer 26
CT (see Table 2)
 
Table 2.
 
SEREX-identified CT Antigens
 
Antigen Chromosomal locus No. of genes in family References
MAGE-1 Xq28 3, 4, 29
13
MAGE-4a Xq28 5, 29, and our unpublished data
SSX2 Xp11.2 5 4, 30
NY-ESO-1 Xq28 2 23, 31, and our unpublished data
SCP1 1p13 Unknown
 
*
 
32
CT7 Unknown 1–2
 
‡
 
Our unpublished data
 
*
 
Southern blot analysis with a SCP1 probe suggests a multigene family.
 
‡
 
Based on Southern blot and preliminary cloning results. 
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can expect that this will be the case for the broad generality
of cancer antigens. In addition, as the development of high
titered IgG requires CD4 T cell help, SEREX provides a
direct route to the analysis of the CD4 T cell repertoire
against tumor antigens. Although antibodies against intra-
cellular proteins, in contrast to CTL against peptides de-
rived from them, cannot generally be expected to have an-
titumor activity, antibodies have enormous advantages over
CTL as probes for structural cloning and monitoring im-
mune responses. The methodology for defining T cell–rec-
ognized tumor antigens has depended on stable T cell lines
and established tumor cell lines, conditions that are fre-
quently difficult to meet and virtually impossible in the case
of certain tumor types. SEREX bypasses both these re-
quirements. Accumulating knowledge about HLA-binding
motifs provides a guide to identifying T cell–recognized
peptides associated with SEREX-defined antigens, and
Jäger et al. (7) have recently used this approach to define
NY-ESO-1 peptides recognized by CTL from a patient
with high NY-ESO-1 antibody titers. SEREX-defined an-
tigens also provide targets to carry out broad scale serologi-
cal surveys of antibody responses in normal individuals and
patients with cancer. Stockert et al. (8) have conducted
such a survey with a panel of tumor antigens, including
several CT antigens, and found that NY-ESO-1 appears to
be particularly immunogenic, with 
 
z
 
40–50% of patients
with NY-ESO-1–expressing tumors developing an anti-
body response at some stage in the disease. With the rapid
increase in the number of SEREX-defined antigens, the
challenge is to choose those with the most promise for fur-
ther analysis. Cancer-restricted immunogenicity, as indi-
cated by a high frequency of antibody response in cancer
patients, is one of the criteria we believe to be of greatest
significance in this selection process. In this context, SEREX
has awakened once again the old hope of finding antibody-
based screening tests for general use in the diagnosis of can-
cer. Finally, SEREX-defined antigens are prime targets for
cancer vaccine development. One of the obstacles con-
fronting the development of maximally immunogenic vac-
cine, whether involving peptide, protein, DNA, or RNA,
is monitoring the immune response to the vaccine. Al-
though most current emphasis is on measuring CTL re-
sponses, serological assays may provide simple and reliable
end points for monitoring the immunogenicity of cancer
vaccines.
 
Address correspondence to Lloyd J. Old, Ludwig Institute for Cancer Research, Memorial Sloan-Kettering
Cancer Center, 1275 York Ave., New York, NY 10021. Phone: 212-639-7526; Fax: 212-717-3100.
 
Received for publication 20 February 1998.
 
References
 
1. Knuth, A., B. Danowski, H.F. Oettgen, and L.J. Old. 1984.
T-cell–medicated cytotoxicity against autologous malignant
melanoma: analysis with interleukin 2–dependent T cell cul-
tures.
 
 Proc. Natl. Acad. Sci. USA. 
 
81:3511–3515.
2. Traversari, C., P. van der Bruggen, B. Van den Eynde, P.
Hainaut, C. Lemoine, N. Ohta, L.J. Old, and T. Boon. 1992.
Transfection and expression of a gene coding for a human
melanoma antigen recognized by autologous cytolytic T lym-
phocytes. 
 
Immunogenetics. 
 
35:145–152.
3. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin,
E. Deplaen, B. Van den Eynde, A. Knuth, and T. Boon.
1991. A gene encoding an antigen recognized by cytolytic T
lymphocytes on a human melanoma. 
 
Science.
 
 254:1643–1647.
4. Sahin, U., Ö. Türeci, H. Schmitt, B. Cochlovius, T. Jo-
hannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M.
Pfreundschuh. 1995. Human neoplasms elicit multiple spe-
cific immune responses in the autologous host. 
 
Proc. Natl.
Acad. Sci. USA.
 
 92:11810–11813.
5. Türeci, Ö., U. Sahin, and M. Pfreundschuh. 1997. Serologi-
cal analysis of human tumor antigens: molecular definition
and implications. 
 
Mol. Med. Today.
 
 3:342–349.
6. Sahin, U., Ö. Türeci, and M. Pfreundschuh. 1997. Serologi-
cal identification of human tumor antigens. 
 
Curr. Opin. Im-
munol.
 
 9:709–716.
7. Jäger, E., Y.-T. Chen, J.W. Drijfout, J. Karback, M. Ring-
hoffer, D. Jäger, M. Arand, H. Wada, Y. Noguchi, E. Stock-
ert, et al. 1998. Simultaneous humoral and cellular immune
response against cancer-testis antigen NY-ESO-1: definition of
HLA-A2–binding peptide epitopes. 
 
J. Exp. Med. 
 
187:265–270.
8. Stockert, E., E. Jäger, Y.-T. Chen, I. Gout, A. Knuth, and L.J.
Old. 1998. A survey of the humoral immune response of
cancer patients to a panel of human tumor antigens. 
 
J. Exp.
Med.
 
 187:1349–1354.
9. Oettgen, H.F., and L.J. Old. 1991. The history of cancer im-
munotherapy. 
 
In 
 
Biologic Therapy of Cancer. V.T. DeVita,
Jr., S. Hellman, and S.A. Rosenberg, editors. J.B. Lippincott
Company, Philadelphia. 87–119.
10. Day, E.A. 1965. The Immunochemistry of Cancer. C.C.
Thomas Publisher, Springfield, IL.
11. Abelev, G.I., S.D. Perova, N.I. Khramkova, Z.A. Postni-
kova, and I.S. Irlin. 1963. Production of embryonal alpha-
globulin by transplantable mouse hepatomas. 
 
Transplantation.
 
1:174–180.
12. Gold, P., and S.O. Freeman. 1965. Specific carcinoembry-
onic antigens of the human digestive system. 
 
J. Exp. Med.
 
122:467–468.
13. Boyse, E.A., and L.J. Old. 1969. Some aspects of normal and
abnormal cell surface genetics. 
 
Annu. Rev. Genet.
 
 3:269–290.
14. Old, L.J., and E. Stockert. 1977. Immunogenetics of cell sur-
face antigens of mouse leukemia. 
 
Annu. Rev. Genet.
 
 11:127–160.
15. Rettig, W.J., and L.J. Old. 1989. Immunogenetics of human
cell surface differentiation. 
 
Annu. Rev. Immunol.
 
 7:481–511.
16. Old, L.J. 1981. Cancer immunology: the search for specific-
ity. G.H.A. Clowes Memorial Lecture. 
 
Cancer Res. 
 
41:361–375.
17. Carey, T.E., T. Takahashi, L.A. Resnick, H.F. Oettgen, and
L.J. Old. 1976. Cell surface antigens of human malignant 
1167
 
Old and Chen
melanoma. I. Mixed hemadsorption assays for humoral im-
munity to cultured autologous melanoma cells. 
 
Proc. Natl.
Acad. Sci. USA. 
 
73:3278–3282.
18. Shiku, H., T. Takahashi, H.F. Oettgen, and L.J. Old. 1976.
Cell surface antigens of human malignant melanoma. II. Se-
rological typing with immune adherence assays and definition
of two new surface antigens. 
 
J. Exp. Med.
 
 144:873–881.
19. Ueda, R., H. Shiku, M. Pfreundschuh, T. Takahashi, L.T.C.
Li, H.F. Oettgen, and L.J. Old. 1979. Cell surface antigens of
human renal cancer defined by autologous typing. 
 
J. Exp.
Med. 
 
150:564–579.
20. Pfreundschuh, M., H. Shiku, T. Takahashi, R. Ueda, J. Ran-
sohoff, H.F. Oettgen, and L.J. Old. 1978. Serological analysis
of cell surface antigens of malignant human brain tumors.
 
Proc. Natl. Acad. Sci. USA.
 
 75:5122–5126.
21. Real, F.X., M.J. Mattes, A.N. Houghton, H.F. Oettgen,
K.O. Lloyd, and L.J. Old. 1984. Class 1 (unique) antigens of
melanoma: identification of a 90,000 dalton cell surface gly-
coprotein by autologous antibody. 
 
J. Exp. Med.
 
 160:1219–
1233.
22. Watanabe, T., C.S. Pukel, H. Takeyama, K.O. Lloyd, H.
Shiku, L.T.C. Li, L.R. Travassos, H.F. Oettgen, and L.J.
Old. 1982. Human melanoma antigen AH is an autoantigenic
ganglioside related to GD2. 
 
J. Exp. Med. 
 
156:1884–1894.
23. Chen, Y.-T., M. Scanlan, U. Sahin, Ö. Türeci, A.O. Gure,
S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and
L.J. Old. 1997. A testicular antigen aberrantly expressed in
human cancers detected by autologous antibody screening.
 
Proc. Natl. Acad. Sci. USA.
 
 94:1914–1918.
24. Brass, N., D. Heckel, U. Sahin, M. Pfreundschuh, G.W.
Sybrecht, and E. Meese. 1997. Translation initiation factor
eIF-4
 
g
 
 is encoded by an amplified gene and induces an im-
mune response in squamous cell lung carcinoma. 
 
Hum. Mol.
Genet. 
 
6:33–39.
25. Güre, A.O., N.K. Altorki, E. Stockert, M.J. Scanlan, L.J.
Old, and Y.-T. Chen. 1998. Human lung cancer antigens
recognized by autologous antibodies: definition of a novel
cDNA derived from the tumor suppressor gene locus on
chromosome 3p21. 
 
Cancer Res. 
 
58:1034–1041.
26. Scanlan, M.J., Y.-T. Chen, B. Williamson, A.O. Gure, E.
Stockert, J.D. Gordan, Ö. Türeci, U. Sahin, M. Pfreundschuh,
and L.J. Old. 1998. Characterization of human colon cancer
antigens recognized by autologous antibodies. 
 
Int. J. Cancer.
 
In press.
27. Türeci, Ö., H. Schmitt, N. Fadle, M. Pfreundschuh, and U.
Sahin. 1997. Molecular definition of a novel human galectin
which is immunogenic in patients with Hodgkin’s disease. 
 
J.
Biol. Chem.
 
 272:6416–6422.
28. Cheever, M.A., M.L. Disis, H. Bernhard, J.R. Gralow, S.L.
Huseby, H.L. Qin, M. Takahashi, and W. Chen. 1995. Im-
munity to oncogenic proteins. 
 
Immunol.
 
 
 
Rev.
 
 145:33–59.
29. De Plaen, E., K.C. Arden, C. Traversari, J. Gaforio, J.-P.
Szikora, C. De Smet, F. Brasseur, P. van der Bruggen, B.
Lethé, O. De Backer, et al. 1994. Structure, localization and
expression of twelve genes of the MAGE family. 
 
Immunoge-
netics. 
 
40:360–369.
30. Güre, A.O., Ö. Türeci, U. Sahin, S. Tsang, M.J. Scanlan, E.
Jäger, A. Knuth, M. Pfreundschuh, L.J. Old, and Y.-T.
Chen. 1997. SSX, a multigene family with several members
transcribed in normal testis and human cancer. 
 
Int. J. Cancer.
 
72:965–971.
31. Chen, Y.-T., A.D. Boyer, C.S. Viars, S. Tsang, L.J. Old, and
K.C. Arden. 1998. Genomic cloning and localization of
CTAG, a gene encoding an autoimmunogenic cancer-testis
antigen NY-ESO-1, to human chromosome Xq28. 
 
Cytoge-
net. Cell Genet.
 
 In press. 
32. Türeci, Ö., U. Sahin, C. Zwick, M. Koslowski, G. Seitz, and
M. Pfreundschuh. 1998. Identification of a meiosis-specific
protein as a new member of the class of cancer/testis antigens.
 
Proc. Natl. Acad. Sci. USA. 
 
In press.
33. Takahashi, K., S. Shichijo, M. Noguchi, M. Hirohata, and K.
Itoh. 1995. Identification of MAGE-1 and MAGE-4 proteins
in spermatogonia and primary spermatocytes of testis. 
 
Cancer
Res.
 
 55:3478–3482.
34. Boel, P., C. Wildmann, M.L. Sensi, R. Brasseur, J. Renauld,
P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: a
new gene encoding an antigen recognized by cytolytic T
lymphocytes.
 
 Immunity.
 
 2:167–175.
35. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S.
Lucas, and T. Boon. 1995. A new family of genes coding for
an antigen recognized by autologous cytotoxic T lympho-
cytes on a human melanoma. 
 
J. Exp. Med.
 
 182:689–698.
36. Crew, A.J., J. Clark, C. Fisher, S. Gill, J. Shipley, A.M.
Chan, B.A. Gusterson, and C.S. Cooper. 1995. Fusion of
SYT to two genes, SSX1 and SSX2, encoding proteins with
homology to the Kruppel-associated box in human synovial
sarcoma. 1995. 
 
EMBO (Eur. Mol. Biol. Organ.) J. 
 
14:2333–
2340.
37. Chen, Y.-T., Y. Obata, E. Stockert, T. Takahashi, and L.J.
Old. 1987. 
 
Tla 
 
region genes and their products. 
 
Immunol.
Res. 
 
6:30–45.
38. De Smet, C., O. De Backer, I. Faraoni, C. Lurquin, F. Bras-
seur, and T. Boon. 1996. The activation of human gene
MAGE-1 in tumor cells is correlated with genome-wide
demethylation. 
 
Proc. Natl. Acad. Sci. USA. 
 
93:7149–7153. 